|
|
 |
|
Viewing report
|
|
|
|
Pancreatic Cancer - Gold Standard Gemcitabine Waiting to be Challenged
Datamonitor, Dec 2004, Pages: 259
Pancreatic adenocarcinoma is the fifth leading cancer-related cause of death and is thus a major health issue in the developed world. Its aggressive nature and resistance to conventional therapy results in an exceedingly poor prognosis, with incidence and age-adjusted mortality rates nearly equivalent.
Report Scope:
Diagnosis patterns of pancreatic adenocarcinoma, including stage distribution, extent of resectability and physician types responsible for diagnosis
Analysis of treatment modalities and regimens based on a survey of 182 clinical oncologists and surgeons across the seven major markets
Percentage of patients enrolled in clinical trials, outcomes of various treatment modalities and key physician prescribing influences
Late-phase pipeline analysis plus insight from interviews with key opinion leaders
Report Highlights:
For the foreseeable future, gemcitabine will remain gold-standard treatment for pancreatic adenocarcinoma and retain its status as market leader. Despite an active late-phase pipeline, no agent is seriously threatening gemcitabines position. Commercial potential will be increased if benefit is demonstrated in combination with gemcitabine.
As a result of exceedingly poor survival rates and a lack of effective treatment options, a major gap in the market exists for reliable and accurate diagnostics to facilitate screening and increase rates of early diagnosis of pancreatic adenocarcinoma. Any company willing to enter this area will be met with a risky, but lucrative opportunity.
Due to low perceived patient potential, pancreatic adenocarcinoma has not traditionally been the focus of clinical trial activity. As a result, discrepancies exist over optimal treatment modalities and regimens. However, this conflict is slowly being resolved with clinical trial data and the advent of molecular targeted therapies.
Reasons to Purchase:
Identify physician types responsible for diagnosis and the key prescribing factors that influence prescription patterns for systemic therapy
Examine the significant unmet need within pancreatic adenocarcinoma and identify opportunities for new product development
Enhance commercial positioning by increasing understanding of current dynamics within the pancreatic adenocarcinoma market
Customers who bought this item also bought
Strategic Perspectives: Pancreatic Cancer - Gemcitabine Combination Therapy is the Future
Stakeholder Opinions: Pancreatic Cancer - Gemzar Dominance will Continue among High Levels of Persistent Unmet Needs
Stakeholder Opinions: Esophageal Cancer Treatment Paradigms Need Revolution Not Evolution
Cell Therapy Clinical Trial Analysis
Stakeholder Insight: Prostate Cancer - Hormone-Refractory Patients Still Waiting For Treatment Breakthroughs
Cell Therapy - Technologies, Markets and Companies
Stakeholder Opinions: Multiple Myeloma - Exploring new targets for multiple drug therapy
Disease Management and Drug Adherence: Strategies to support patients and enhance treatment persistence
Gene Therapy - Technologies, Markets and Companies
Pharmacogenomics for Clinical Use and in Drug Development
Stakeholder Insight: Parkinsons Disease - Evidence of neuroprotection essential to progress treatment dynamics
Stakeholder Insight: HIV Therapy Dynamics
|
|
|
|
